Loading...
01/10 16:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals. While there are positive aspects like the acquisition of Paragon 28, strong July performance, and optimism about Monogram's technology, there are concerns about reduced EPS guidance, tariff impacts, and declining operating margins. The Q&A section shows confidence in growth but lacks specific guidance for 2026. The neutral sentiment reflects these balanced positive and negative factors.
Organic constant currency sales growth 2.8% year-over-year. This growth occurred despite an 80 basis point selling day headwind and delays in international orders, which were moved to the third quarter.
U.S. Hips business growth 5.2% year-over-year, an acceleration from 3.7% growth in Q1 2025. This was driven by strong adoption of the Z1 triple taper stem for direct anterior hip procedures.
U.S. Knees business growth 1.7% year-over-year, with a sequential increase of 150 basis points. Growth was supported by increasing penetration of the Persona OsseoTi cementless total knee and early adoption of the Oxford partial cementless knee.
S.E.T. segment growth 4.9% year-over-year on an organic basis. This marks the seventh consecutive quarter of mid-single-digit growth, driven by double-digit growth in Sports Medicine and CMFT, and high single-digit growth in upper extremities.
Adjusted earnings per share (EPS) $2.07, up 3% year-over-year. This increase was achieved despite dilution from the Paragon 28 transaction and continued investments in the commercial organization.
Net sales $2.77 billion, an increase of 7% on a reported basis and 2.8% on an organic constant currency basis. Growth was driven by strong performance in U.S. Hips and Knees, as well as the S.E.T. segment.
Adjusted gross margin 72.3%, higher than the prior year due to favorable mix and lower excess and obsolescence costs, which offset higher manufacturing costs.
Adjusted operating margin 27.8%, lower than the prior year due to increased commercial investments and the addition of Paragon 28, but in line with expectations.
Free cash flow $248 million, in line with 2024 levels despite the Paragon 28 acquisition. This was supported by working capital initiatives, including a reduction in inventory days on hand by almost 20 days compared to Q2 2024.
New Product Launches: Zimmer Biomet introduced several new products, including the Z1 triple taper stem for direct anterior hip procedures, Persona OsseoTi cementless total knee, and Oxford partial cementless knee. These products are driving competitive conversions and strong adoption rates.
Robotics and AI: Zimmer Biomet announced the acquisition of Monogram Technologies, which developed the mBôs robot with semi and fully autonomous AI-driven robotic capabilities. This technology is expected to transform orthopedic surgery.
S.E.T. Segment: The S.E.T. segment, including Sports Medicine and CMFT, reported mid-single-digit growth, driven by new product launches and strong adoption of solutions like the Identity total shoulder and OsseoFit stemless shoulder.
Geographic Expansion: The company reported strong growth in the U.S. market, particularly in hips and knees, and noted increasing adoption of its products in Europe, including the Persona Revision knee.
Operational Efficiency: Zimmer Biomet reduced inventory days on hand by almost 20 days compared to the previous year, improving free cash flow generation. The company also mitigated tariff impacts and optimized supply chain operations.
Revenue and Earnings Growth: The company updated its 2025 revenue growth guidance to 3.5%-4.5% and raised its adjusted EPS guidance to $8.10-$8.30, reflecting confidence in operational efficiencies and new product performance.
M&A Strategy: Zimmer Biomet completed the acquisition of Paragon 28 and announced plans to acquire Monogram Technologies, aligning with its strategy to diversify into higher-growth segments.
People and Culture: The company emphasized its focus on people and culture, including the appointment of Kevin Thornal as Group President for Global Businesses and the Americas to drive growth and commercial excellence.
International Order Delays: Significant delays in international orders have shifted revenue recognition to the third quarter, potentially impacting cash flow and operational planning.
Tariff Impact: Although reduced, tariffs are still expected to create a $40 million headwind to operating profit in 2025, primarily in the second half.
Debt and Interest Expenses: Higher debt levels and increased interest rates due to the Paragon 28 acquisition have raised interest expenses, impacting profitability.
Operational Margin Pressure: Adjusted operating margin is expected to decline by about 100 basis points in 2025 due to increased commercial investments and acquisition-related costs.
Supply Chain Challenges: Efforts to mitigate global tariffs and supply chain disruptions are ongoing, but these issues remain a risk to operational efficiency.
Product Launch Risks: The success of new product launches, including the 'magnificent 7,' is critical for second-half growth acceleration, but adoption and execution risks exist.
M&A Integration Risks: The integration of recent acquisitions like Paragon 28 and Monogram Technologies poses challenges, including achieving expected synergies and managing operational complexities.
Full Year Organic Constant Currency Revenue Growth: Updated to a range of 3.5% to 4.5% from the previous 3% to 5% range, excluding the contribution of Paragon 28.
Paragon 28 Contribution: Expected to contribute 270 basis points to sales growth projection in 2025.
Adjusted Earnings Per Share Guidance: Raised to $8.10 to $8.30 from the previous range of $7.90 to $8.10.
Second Half 2025 Sales Acceleration: Driven by new product cycle, increased operational efficiency, lower tariff impact, and FX benefit.
Revenue Growth from Monogram Acquisition: Expected to begin in 2027, with high single-digit ROIC by year 5 and increasing contribution starting in year 6.
New Product Launches: Expected to drive growth in U.S. Hips, U.S. Knees, and S.E.T. segments in the second half of 2025 and beyond.
Adjusted Operating Margin: Expected to be down about 100 basis points from 2024, with the highest margin in Q4 2025.
Free Cash Flow: Projected to be $1 billion to $1.2 billion for 2025.
Tariff Impact: Lowered to a $40 million headwind to operating profit in 2025, down from $60 million to $80 million.
FX Tailwind: Expected to contribute 50 basis points of growth in 2025.
share repurchases: Fully diluted shares outstanding were 198.3 million, down year-over-year due to the share repurchases from last year and in the first quarter of 2025.
The earnings call summary presents mixed signals. While there are positive elements like raised EPS guidance and new product launches, concerns arise from declining operating margins and uncertainties in international markets. The Q&A reveals cautious management responses, a choppy U.S. revision market, and market share loss in U.S. knees. Although optimistic guidance and potential premium pricing for iodine-coated implants are positive, the lack of specific guidance for 2026 and cautious capital allocation strategy tempers expectations. Overall, the sentiment is neutral, with potential upside from innovation and strategic acquisitions.
The earnings call reveals mixed signals. While there are positive aspects like the acquisition of Paragon 28, strong July performance, and optimism about Monogram's technology, there are concerns about reduced EPS guidance, tariff impacts, and declining operating margins. The Q&A section shows confidence in growth but lacks specific guidance for 2026. The neutral sentiment reflects these balanced positive and negative factors.
The earnings call reflects several concerns: ongoing operational challenges, economic factors affecting revenue growth, and a significant tariff impact on profits. Despite new product launches and share repurchases, the guidance for free cash flow and EPS has been lowered. The Q&A section highlights uncertainties regarding tariff mitigation and sales force reorganization. These factors, combined with modest acquisition dilution and a cautious market outlook, suggest a likely negative stock reaction in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
